Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$5.72
-$0.17(-2.86%)
At close: 4:00 PM EDT
$5.72
-$0.17(-2.86%)
Day’s Range― - ―
52-Week Range$4.91 - $13.15
Previous CloseN/A
Volume674.69K
Average Volume (3M)2.11M
Market Cap
$578.78M
Enterprise Value$748.32
Total Cash (Recent Filing)$143.84M
Total Debt (Recent Filing)$171.60M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 17, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding99,447,340
10 Day Avg. Volume1,513,469
30 Day Avg. Volume2,107,072
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside424.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.73
Revenue Forecast (FY)$139.83M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption Is AcceleratingRapid gains in market share and prescriber adoption indicate neffy is establishing a stronger commercial foothold. Continued uptake among targeted providers could support durable revenue growth as the company expands prescribing behavior beyond early adopters.
Strong Product-level Gross MarginsGross margins above 60% demonstrate attractive product economics and provide operating leverage potential as manufacturing scales. If launch-related inefficiencies and inventory charges moderate, improving margins could support a more sustainable commercial model.
Targeted Cost Discipline Supports A Breakeven PathThe planned shift toward focused provider coverage and materially lower cash-based spending could extend the company’s runway and reduce operating losses. Successful execution would improve capital efficiency while preserving investment in the highest-value commercial opportunities.
Bears Say
Severe Operating Losses RemainCurrent revenue is far below the cost base, leaving the company dependent on continued financing while it scales neffy. The magnitude of losses creates substantial execution risk and means profitability remains highly sensitive to adoption, pricing, and spending control.
Heavy Cash Burn And Fragile LiquidityPersistent cash consumption limits financial flexibility and may require additional funding before the targeted 2027 breakeven point. External financing could increase dilution or refinancing risk, particularly if commercial growth fails to offset ongoing expenses.
Leverage And Commercial Access PressuresA highly leveraged capital structure compounds risk if payer friction, discounts, and rebates constrain realized revenue. Prior authorization and gross-to-net pressure can slow adoption and weaken cash conversion, making the path from strong product margins to corporate profitability harder.
ARS Pharmaceuticals News
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $4.91 and its highest was $13.15 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $578.78M.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Nov 17, 2026 which is in 74 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.152.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.29.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 99,447,340 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -7.377%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (424.48% Upside)
$30.00 (424.48% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 71%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SPRY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging commercial momentum and a clear strategic reset with notable operational and financial challenges. Positive indicators include doubled overall market share (2.5% to 5%), an 8% share in field-targeted accounts, triple+ growth in unique prescribers, a completed sales-force expansion, hiring of an experienced CCO, and a plan to reduce cash-based SG&A by over 40% in H2 with a stated path to cash-flow breakeven by end of 2027. Offsetting these positives are high Q2 operating expenses (~$95.1M), elevated SG&A (~$77.6M), gross-to-net pressure near ~50%, manufacturing/short-dated inventory impacts on margins, payer prior-authorization friction (only ~57% without PA) and a modest delay in the CSU Phase IIb interim readout to Q1 2027. Overall, the company presented a constructive corrective plan but material execution and margin risks remain.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$30.00
▲(424.48% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
27.19% Insiders
6.92% Mutual Funds
56.04% Other Institutional Investors
0.31% Public Companies and
Individual Investors